retatrutide ada 2025 results 2026: Obesity Pharmacotherapy Trends Through 2030 | Ney Carter Borges MD M.Sc. Ph.D FESC,FACC,FAHA,FACP. posted on the topic Retatrutide approval: FDA status, clinical

Learn common causes of dizziness with GLP-1 therapy and ways to support hydration, nutrition, and recovery.

Instead of letting fatigue and occasional nausea derail your day, pour yourself a refreshing glass of SoWell Electrolytes lemon water

Injection bruising is common but preventable

For many people using GLP-1 medications, eating enough protein can feel challenging

GLP-1 injections across Vermont (VT), online

Amongst, overweight and obese patients defined by BMI in 2024 (58.9% [95% CIs 53.3-64.2%] female [182/309], median [IQR] age 56.6 [46.2-66.1]) GLP 1RA use has increased from 3.2% (10/309 [95% CIs 1.8-5.9%]) to 13.6% (42/309 [95% CIs 10.2-17.9%] [p=7.1x10-6])